HERON THERAPEUTICS INC (HRTX)
Health Care · Biotechnology · NASDAQ
Heron Therapeutics is a biotech company focused on commercializing extended-release postoperative pain and antiemetic therapies for acute care and oncology patients.
What HERON THERAPEUTICS INC does
Heron Therapeutics is a commercial-stage biotechnology company that develops and markets therapeutic products for acute care and oncology supportive care. Its portfolio centers on pain management and antiemetic therapies, utilizing a proprietary sustained-release polymer platform known as Biochronomer technology. The company focuses on improving standard-of-care treatments for postsurgical pain and chemotherapy-induced nausea and vomiting.
Recent developments
The company has withdrawn its 2026 financial guidance due to an adverse district court ruling on CINVANTI patents and is actively exploring strategic alternatives. Additionally, it has amended its credit facility to reset financial covenants and reduce outstanding principal through September 2026.
From HERON THERAPEUTICS INC's filing of 2026-08-10.
Themes: postoperative pain management, oncology supportive care, antiemetics, drug delivery systems, acute care surgery
Fundamentals
- Price$0.3582 as of 2026-10-08 close
- Market cap$68M as of 2026-08-05 (share count; price 2026-10-08)
- 1-year return-73.5% 2025-10-08 close $1.35 → 2026-10-08 close $0.3582
- P/En/a negative earnings
- ROE-140.9% FY2025, SEC XBRL
- Debt / equity20.65 as of 2026-09-03
- Revenue growth (YoY)+1.0% as of 2026-09-03
- Beta1.11 as of 2026-09-03
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How HRTX compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How HERON THERAPEUTICS INC looks technically
HERON THERAPEUTICS INC (HRTX) is trading 54.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 280 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 2 trading days ago. It is 77.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 54.8% below its 200-day average, the long-term trend line — a long-term downtrend | -54.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.3474 | $0.3474 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $0.7929 | $0.7929 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 280 trading days ago — a "death cross", a bearish long-term signal | 280 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($0.26 to $0.41) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 65.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $1.58 | $1.58 |
|---|---|---|
| From the 52-week high | it is 77.3% below its 52-week high (its highest price of the past year) | -77.3% |
| Above the 52-week low | it is 37.8% above its 52-week low (its lowest price of the past year) | +37.8% |
| Below the 52-week high | it is 77.3% below its highest point of the past year | 77.3% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $185.60 (set on 2006-02-01) | $185.60 |
| Given back of the 52-week move | over the past year its closes ranged ($0.27 to $1.49), and it has recovered only a small part of its fall from last year’s high — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.02 to $1.06. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.2% |
| From the all-time high | it is 99.8% below its all-time high | -99.8% |
| Nearest price level | it is trading 16.4% above a support level at $0.2996 — a price it turned at twice since 2026-08-20, most recently on 2026-09-01. Since 2024-10-08 it has 1 such level below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -16.4% |
| All-time low | its lowest closing price on record is $0.26 (set on 2026-09-21) | $0.26 |
| Above the all-time low | it is 37.8% above its all-time low | +37.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 46th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0338 between its high and its low — about 9.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0338 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.26 and $0.38 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.26 – $0.32 – $0.38 |
| Typical daily range (% of price) | its price moves about 9.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.4% |
| Stretch from the 200-day average | it is trading 12.9 daily ranges below its 200-day average price (54.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.82× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.8% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 12 sessions ago and has not traded back through the level it left behind at 0.27 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 2.9% gap up opened on 2026-10-05 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.3 percentage points (the stock gained 2.3% while the market gained 1.0%) | +1.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 23.4 percentage points (the stock lost 19.6% while the market gained 3.8%) | -23.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 73.3 percentage points (the stock lost 55.8% while the market gained 17.5%) | -73.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 88.4 percentage points (the stock lost 73.5% while the market gained 15.0%) | -88.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 13.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -3.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 47% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $0.6794 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -47.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $0.3221 — a volume-weighted average of daily closes over 43 sessions, not a true tick-by-tick VWAP. | +11.2% |
Price levels it has turned at before
HRTX last closed at $0.3582 on 2026-10-08. Since 2024-10-08 it has turned at 1 price below its last close and 11 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.2996 | Support | 16.4% below the last close | turned there twice · 2026-08-20 to 2026-09-01 |
| $1.05 | Resistance | 192.4% above the last close | turned there four times · 2024-11-12 to 2026-02-25 |
| $1.19 | Resistance | 230.8% above the last close | turned there four times · 2025-08-11 to 2026-01-05 |
| $1.33 | Resistance | 272.7% above the last close | turned there twice · 2026-02-26 to 2026-05-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · lagging the market · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$7.00 range $5.00 – $9.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HRTX
- Consensus EPS estimate-$0.025 next reporting period, as of 2026-10-09
- Estimate change, 30 days-$0.005 from -$0.02, on 2026-09-04, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Uncertainty regarding potential generic competition for CINVANTI following an adverse court ruling.","Financial instability and potential for significant dilution or restructuring while pursuing strategic alternatives.","High dependence on the continued commercial adoption and reimbursement of key products ZYNRELEF and APONVIE."]
What changed in the latest 10-Q
AI-assisted comparison of HRTX's 10-Q filed 2026-05-11 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-11) states: 'Through March 31, 2025, ZYNRELEF was reimbursed outside of the surgical bundle payment in the HOPD setting of care through pass-through status granted by CMS.'
- Newer filing (2026-05-11) states: 'Effective April 1, 2025, ZYNRELEF is reimbursed through inclusion in the NOPAIN Act' with detailed qualification requirements.
- Newer filing (2026-05-11) states: 'Effective October 1, 2025, CMS has approved a new permanent Healthcare Common Procedure Coding System J-code for ZYNRELEF.'
- Newer filing (2026-05-11) states regarding APONVIE: 'CMS granted pass-through payment status for APONVIE, effective April 1, 2023, which expired March 31, 2026. Effective April 1, 2026, CMS has approved a new permanent Healthcare Common Procedure Coding System J-code for APONVIE.'
- Newer filing (2026-05-11) states: 'In 2025, APONVIE was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting as published in Anesthesia and Analgesia.'
- Removed:
- Older filing (2025-11-04) states: 'In March 2022, the Centers for Medicare and Medicaid Services ("CMS") approved a 3-year transitional pass-through status of ZYNRELEF, which became effective on April 1, 2022 and expired March 31, 2025.'
- Older filing (2025-11-04) states: 'In addition, in December 2022, H.R. 2617, the omnibus spending bill was approved by Congress, which includes the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act which directs CMS...' [entire legislative history removed]
- Older filing (2025-11-04) states NOPAIN Act reimbursement would begin: 'from April 1, 2025, through December 31, 2027' [phrasing changed in newer]
- Older filing (2025-11-04) describes APONVIE as 'the first and only intravenous formulation of a substance P/neurokinin-1' [wording differs from newer]
- Older filing (2025-11-04) states for APONVIE pass-through: 'CMS granted pass-through payment status for APONVIE, effective April 1, 2023.' [no expiration date mentioned]
- Reworded:
- Older filing references '2024 Annual Report'; newer filing references '2025 Annual Report'
- Older filing compares results for 'three and nine months ended September 30, 2025 and 2024'; newer filing compares 'three months ended March 31, 2026 and 2025'
- Older filing references cash flow analysis for 'nine months ended September 30, 2025 and 2024'; newer filing references 'three months ended March 31, 2026 and 2025'
- Older filing references commitments 'as of September 30, 2025'; newer filing references 'as of March 31, 2026'
- APONVIE description changed from 'a substance P/neurokinin-1' to 'aprepitant, a substance P/neurokinin-1' in newer filing
- Notes:
- The newer filing text appears truncated at the CINVANTI section and does not include the full CINVANTI description present in the older filing, preventing complete comparison of that section.
- Comparison reflects changes between Q3 2025 filing and Q1 2026 filing, representing different fiscal periods.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for HRTX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding HRTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 15,607,210
- Reported value $6,661,157
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about HRTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
HRTX had 43,380,273 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
HRTX had 22.8% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 27.84 days to cover at the same settlement.
- Reported short interest (shares) 43,380,273
- Short interest (% of shares outstanding) 22.8%
- Prior settlement (shares) 44,864,084
- Reported change -3.31%
- Days to cover (reported) 27.84
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pacira BioSciences (PCRX)
- Helsinn Therapeutics
- Teva Pharmaceutical (TEVA)
- Hikma Pharmaceuticals
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HRTX vs…
HRTX ranks in…
Frequently asked questions
What does HERON THERAPEUTICS INC (HRTX) do?
Heron Therapeutics is a commercial-stage biotechnology company that develops and markets therapeutic products for acute care and oncology supportive care. Its portfolio centers on pain management and antiemetic therapies, utilizing a proprietary sustained-release polymer platform known as Biochronomer technology. The company focuses on improving standard-of-care treatments for postsurgical pain and chemotherapy-induced nausea and vomiting.
What sector is HERON THERAPEUTICS INC (HRTX) in?
HERON THERAPEUTICS INC (HRTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are HERON THERAPEUTICS INC's (HRTX) competitors?
Notable peers of HERON THERAPEUTICS INC (HRTX) include Pacira BioSciences, Helsinn Therapeutics, Teva Pharmaceutical and Hikma Pharmaceuticals. This peer set is informational only — not financial advice.
Is HERON THERAPEUTICS INC (HRTX) overbought or oversold right now?
HERON THERAPEUTICS INC (HRTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HRTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.